Tigecycline, an antibiotic already approved by the United States’ Food and Drug Administration, can selectively kill leukemia cells and leukemia stem cells by shutting down the energy supply in these cells. Since Tigeycline is already approved to treat complex infections, re-profiling Tigecycline for leukemia treatment will accelerate its path to preclinical and clinical testing as a significant amount of the existing data can be leveraged for the new profile.
Inventor
Status Currently being tested in a Phase I clinical trial in leukemia patients.